An iron-chelated phospholipid molecule and its application in lipid nanoparticle delivery systems
By introducing iron-chelated phospholipid molecules into lipid nanoparticles, the interaction between the iron chelating groups and the endosome/lysosome membranes is utilized to achieve efficient escape and cytoplasmic release of nucleic acid drugs, solving the problem of low delivery efficiency in existing technologies and reducing liver targeting and cytotoxicity.
Patent Information
- Application Number
- CN202611322809.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-28
- Publication Date
- 2026-11-17
AI Technical Summary
Existing lipid nanoparticle delivery systems have difficulty escaping endosomal or lysosome endocytosis, resulting in low delivery efficiency as nucleic acid drugs cannot be effectively released into the cytoplasm.
A novel iron-chelated phospholipid molecule was designed. By introducing iron chelating groups into lipid nanoparticles, the iron-chelated phospholipids formed stable iron-phospholipid coordination complexes with iron ions in the endosome/lysosome microenvironment, triggering a membrane structure phase transition and disrupting the integrity of the endosome/lysosome membrane, thereby achieving efficient escape of nucleic acid molecules and release of cytoplasm.
It significantly improved the endosome escape efficiency and cytoplasmic release of nucleic acid molecules, enhanced the delivery efficiency of nucleic acid drugs, and reduced the liver targeting and cytotoxicity of traditional lipid nanoparticles.
Smart Images

Figure CN123106764A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, and in particular to an iron-chelated phospholipid molecule and its application in lipid nanoparticle delivery systems. Background Technology
[0002] Nucleic acid drugs, including messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), and DNA, are a class of biological drugs that can treat diseases by regulating gene expression. In recent years, with the development of gene therapy technology, mRNA drugs have shown broad application prospects in vaccine development, protein replacement therapy, and tumor immunotherapy. However, their molecules are characterized by large molecular weight, negative charge, and susceptibility to degradation by nucleases in the body, making them difficult for cells to take up. Therefore, nucleic acid drugs require delivery vectors to exert their effects in the cytoplasm or nucleus.
[0003] Lipid nanoparticles (LNPs) are one of the most mature mRNA delivery systems currently available. LNPs typically consist of ionizable lipids, cholesterol, helper phospholipids, and polyethylene glycol-modified lipids, which self-assemble into nanoparticle structures to encapsulate nucleic acid drugs and enter cells via endocytosis. However, in existing LNP systems, most of the drugs are trapped in endosomes or lysosomes after cellular uptake and are either degraded or exoccluded, making effective release into the cytoplasm difficult. This results in mRNA translation failure and low delivery efficiency. Improving the endosome escape efficiency of delivery vectors is crucial for enhancing nucleic acid delivery efficiency. Therefore, how to rationally design and optimize LNP vectors to significantly improve endosome escape efficiency has become a recognized core scientific problem and a key direction for technological breakthroughs in the field of nucleic acid delivery. Summary of the Invention
[0004] To address the aforementioned technical problems, this invention provides an iron-chelated phospholipid molecule and its application in a lipid nanoparticle delivery system. The iron-chelated phospholipid molecule and the lipid nanoparticles (LNPs) it constitutes possess iron-chelating ability, exhibit high drug delivery efficiency and low cytotoxicity, and can achieve efficient escape of nucleic acid molecules and release of cytoplasm.
[0005] To achieve the above objectives, the present invention provides an iron-chelated phospholipid molecule, wherein the iron-chelated phospholipid molecule is a phospholipid derivative with an amphiphilic structure, comprising a hydrophilic head group and a hydrophobic fatty chain, wherein the hydrophobic fatty chain has an iron-chelating group; the iron-chelated phospholipid molecule comprises one of the structural formulas of Formula I, or its tautomers, stereoisomers, solvates or pharmaceutically acceptable salts; in the structural formula, X is a hydrophilic head group, R1 is a carbonyl-containing saturated or unsaturated fatty chain, R2 is an iron-chelating group, and L is a bifunctional linker bond; Formula I.
[0006] Preferably, the hydrophilic head group X is one of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, or a derivative thereof; the carbon chain length of the carbonyl-containing saturated or unsaturated aliphatic chain R1 is 8-24; the iron chelating group R2 is one of derafloxacin, pyridones, catechols, pyrogallols, bispyridinemethylamines, bispiperidinepyridines, amides, triazoles, deferoxones, deferoxamines, or their derivatives; and the bifunctional linker L is a saturated aliphatic chain with a carbon chain length of 0-10, with one end being an ester bond connected to the glycerol backbone and the other end being an amide bond connected to the iron chelating group.
[0007] Preferably, the hydrophilic head group X is phosphatidylcholine, the hydrophobic fatty chain R1 is a C18 fatty chain, the iron chelating group R2 is deferasirox or a derivative thereof, and the bifunctional linker L is one of a saturated fatty chain with a carbon chain length of 2, 4, or 6.
[0008] Preferably, the hydrophilic head group X is phosphatidylcholine; the hydrophobic fatty chain R1 is a C18 fatty chain; and the iron chelating group R2 is derafloxacin or a derivative thereof.
[0009] This invention also provides the application of iron-chelated phospholipid molecules as described above in the preparation of lipid nanoparticles.
[0010] The present invention also provides a lipid nanoparticle comprising the following components: iron chelated phospholipid molecules as described above, cationic lipids or ionizable lipids, neutral lipids, steroids and polyethylene glycol modified lipids; wherein the molar ratio of the iron chelated phospholipid molecules, cationic lipids or ionizable lipids, neutral lipids, steroids and polyethylene glycol modified lipids is (1~20):(20~60):(5~30):(20~50):(0.2~5); or (5~15):(40~60):(5~20):(20~40):(0.5~3).
[0011] The present invention also provides a lipid nanoparticle delivery system, comprising the lipid nanoparticles described above and a bioactive component; the lipid nanoparticles contain iron-chelated phospholipid molecules as described above, and the bioactive component comprises one or more of DNA molecules, RNA molecules, proteins, peptides, and small molecule drugs.
[0012] This invention also provides the application of the iron-chelated phospholipid molecules, nanoparticles, and lipid nanoparticle delivery systems described above in drug preparation.
[0013] The present invention also provides a pharmaceutical composition comprising the lipid nanoparticle delivery system described above and pharmaceutically acceptable excipients.
[0014] This invention also provides the application of iron-chelated phospholipid molecules, nanoparticles, lipid nanoparticle delivery systems, and pharmaceutical compositions as described above in improving drug delivery efficiency.
[0015] Compared with the prior art, the present invention has the following technical effects: This invention discloses an amphiphilic phospholipid molecule with a specific iron-chelating group. This phospholipid molecule and the lipid nanoparticles (LNPs) it constitutes possess iron-chelating capabilities, exhibiting high drug delivery efficiency and low cytotoxicity. By adjusting the proportion of iron-chelated phospholipids in the LNPs, the particle size, surface charge, encapsulation efficiency of bioactive components such as mRNA, and delivery efficiency of the nanoparticles can be precisely controlled. When LNPs containing this compound are endocytosed into endosomes / lysosomes, the iron-chelated phospholipids form stable iron-phospholipid coordination complexes with iron ions in the endosome / lysosome microenvironment. These complexes then interact with the endosome / lysosome membrane, triggering a structural phase transition of the lipid bilayer membrane from a lamellar phase (Lα) to a non-lamellar phase (such as the HII phase), disrupting the integrity of the endosome / lysosome membrane, and ultimately achieving efficient escape of nucleic acid molecules and release into the cytoplasm. Meanwhile, this iron-chelated phospholipid component can regulate the spleen enrichment of LNPs and nucleic acid drugs, solving the common liver targeting and toxic side effects of traditional LNPs, and can be used as an iron-chelated drug delivery carrier in the biomedical field. Attached Figure Description
[0016] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0017] Figure 1 A schematic diagram of the synthetic route for the iron-chelated phospholipid molecule Lyso-DFX; Figure 2 Lyso-DFX is an iron-chelated phospholipid molecule. 1 H NMR spectrum; Figure 3 A schematic diagram of the synthetic route for the iron-chelated phospholipid molecule Lyso-C2-DFX; Figure 4 A schematic diagram of the synthetic route for the iron-chelated phospholipid molecule Lyso-C4-DFX; Figure 5 A schematic diagram of the synthetic route for the iron-chelated phospholipid molecule Lyso-C6-DFX; Figure 6 Lyso-C2-DFX is an iron-chelated phospholipid molecule. 1 H NMR spectrum; Figure 7 Lyso-C4-DFX is an iron-chelated phospholipid molecule. 1 H NMR spectrum; Figure 8 Lyso-C6-DFX is an iron-chelated phospholipid molecule. 1 H NMR spectrum; Figure 9 Lyso-C with different carbon chain lengths n Comparison of Luciferase mRNA expression levels of -DFX in HEK-293T cells; In the figure, F0 represents the four-component LNP containing Dlin-MC3-DMA, A7-0C represents the LNP based on Dlin-MC3-DMA with Lyso-DFX introduced in the A7 ratio, A7-2C represents the LNP based on Dlin-MC3-DMA with Lyso-C2-DFX introduced in the A7 ratio, A7-4C represents the LNP based on Dlin-MC3-DMA with Lyso-C4-DFX introduced in the A7 ratio, and A7-6C represents the LNP based on Dlin-MC3-DMA with Lyso-C4-DFX introduced in the A7 ratio. The following LNPs are introduced in different formulations: B5-0C is based on Dlin-MC3-DMA, and B5-2C is based on Dlin-MC3-DMA, and B5-4C is based on Dlin-MC3-DMA, and B5-6C is based on Dlin-MC3-DMA, and B5-6C is based on Dlin-MC3-DMA, and B5-6C is based on Dlin-MC3-DMA, and B5-6C is based on Dlin-MC3-DMA, and B5-6C is based on Dlin-MC3-DMA, and B5-6C is based on Dlin-C6-DFX. express P <0.01; Figure 10This study evaluates the delivery efficiency and cytotoxicity of iron-chelated lipid nanoparticles in different cell types, at different times, and with different mRNA doses. Specifically, a~c represent the luminescence intensity of LNPs (F0 and B5) loaded with different concentrations of firefly luciferase mRNA in the MC3 system after incubation in HEK-293T cells for 24h, 36h, and 48h, respectively; d~f represent the luminescence intensity of LNPs (S0 and C4) loaded with different concentrations of firefly luciferase mRNA in the SM-102 system after incubation in HEK-293T cells for 24h, 36h, and 48h, respectively; g represents the survival rate of HEK-293T cells treated with different concentrations of LNPs (F0, B5, S0, or C4); and h represents the luminescence intensity of Luciferase in different cell lines. The results of the comparison of mRNA expression levels are shown in the figure; F0 is the four-component LNP containing Dlin-MC3-DMA, B5 is the LNP prepared by the B5 formulation, S0 is the four-component LNP based on the ionizable lipid SM-102, and C4 is the LNP prepared by the C4 formulation. express P <0.05, express P <0.01, express P <0.001; Figure 11 This section illustrates cellular uptake and endosome escape of iron-chelated lipid nanoparticles. Figure a shows the inhibition of iron-chelated LNP uptake by different endocytosis inhibitors; figure b shows confocal microscopy images of the colocalization of Cy5-labeled mRNA lipid nanoparticles (LNPs, F0 and B5 types) with endosomes / lysosomes in HEK-193T cells (lysosome tracer green fluorescence: excitation wavelength 488 nm / emission wavelength 503–550 nm; Cy5 red fluorescence: excitation wavelength 638 nm / emission wavelength 650–700 nm), with scale bars: magnified images at 3 μm, and other images at 25 μm; figure c shows the colocalization analysis in figure b. ns indicates no significant difference. express P <0.05, express P <0.01; Figure 12 Lyso-DFX and Fe at different pH values 2+ Absorption spectra and images of the complexation reaction, where a is the absorption spectrum and b is the image; in the image, pH 7.4 Lyso-DFX+Fe 2+ This represents Lyso-DFX chelating with Fe2+ at pH 7.4, and Lyso-DFX + Fe2+ at pH 6.3. 2+ Represents Lyso-DFX with Fe under pH 6.3 conditions 2+ Chelation, pH 5.5 Lyso-DFX+Fe2+ Represents Lyso-DFX with Fe under pH 5.5 conditions. 2+ Chelation, Lyso-DFX represents lipid suspension, Fe 2+ Represents Fe 2+ Solution; Figure 13 For Lyso-DFX and Fe 2+ DSC thermal image of the formed chelate; Figure 14 This diagram illustrates the hemolytic activity of different concentrations of Lyso-DFX at various pH values. pH 7.4 represents the hemolytic activity of Lyso-DFX with Fe. 2+ The reaction was carried out at pH 7.4, with pH 5.5 representing the reaction between Lyso-DFX and Fe. 2+ The reaction was carried out at pH 5.5. express P <0.001; Figure 15 The effect of Lyso-DFX on vesicle membrane fluidity under different conditions was investigated. In this study, a represents the GP values of different final Lyso-DFX concentrations at pH 7.4 (control group), b represents the GP values of different final Lyso-DFX concentrations at pH 6.3 (control group), c represents the GP values of different final Lyso-DFX concentrations at pH 5.5 (control group), and d represents the GP values of vesicles containing Fe. 2+ GP values of different final Lyso-DFX concentrations at pH 7.4, where e represents the Fe content. 2+ GP values of different final Lyso-DFX concentrations under pH 6.3 conditions, where f represents the Fe content. 2+ GP values of different final Lyso-DFX concentrations under pH 5.5 conditions; Figure 16 To add Fe 2+ Before and after, preloaded with vesicles of different proportions of Lyso-DFX 31 P nuclear magnetic resonance spectrum, in which CtlVesicles represent the control group, 10mol% Lyso-DFX Vesicles represent the 10mol% Lyso-DFX group, and 25mol% Lyso-DFX Vesicles represent the 25mol% Lyso-DFX group; Figure 17This is a schematic diagram of bioluminescence distribution in mice. In the diagram, a represents the bioluminescence intensity of different formulations of LNPs carrying luciferase mRNA in mice 6 hours after tail vein injection, and b represents the distribution of different formulations of LNPs carrying luciferase mRNA in the main organs of mice 6 hours after tail vein injection. L0 represents a four-component commercial formulation of LNPs without Lyso-DFX, and L1 represents an optimized five-component formulation of LNPs containing Lyso-DFX. Figure 18 Figure 1 shows the results of a mouse melanoma treatment experiment. Figure 2 shows the establishment of the mouse melanoma model and the drug administration process, illustrating the timing of subcutaneous B16F10 cell inoculation and tail vein administration. Figure 3 shows the tumor volume change curves of mice in different treatment groups during the experiment. Figure 4 shows the tumor weight statistics for each group at the end of the experiment. Figure 5 shows the body weight change curves of mice in different treatment groups during the experiment. Figure 6 shows the IFN-γ level detection results in tumor tissue homogenate. Figure 7 shows the TNF-α level detection results in tumor tissue homogenate. Figure 8 shows the CD8a (red) and CD9a levels in tumor tissues of different treatment groups. Representative images of DAPI (blue) immunofluorescence staining, scale bar at 58 μm. h represents quantitative analysis of fluorescence signal; i represents the ALT result in the plasma of mice in each group; j represents the AST result in the plasma of mice in each group; k represents the BUN result in the plasma of mice in each group; l represents the CRE result in the plasma of mice in each group. In the figures, PBS represents the control group, L0-LNP-OVA represents the LNPs treatment group without Lyso-DFX, and L1 represents the LNPs treatment group containing Lyso-DFX. express P <0.05, express P <0.01, express P <0.0001. Detailed Implementation
[0018] This invention provides an iron-chelated phospholipid molecule, which is a phospholipid derivative with an amphiphilic structure, comprising a hydrophilic head group and a hydrophobic fatty chain, wherein the hydrophobic fatty chain has an iron-chelating group; the iron-chelated phospholipid molecule comprises one of the structural formulas of Formula I, or its tautomers, stereoisomers, solvates or pharmaceutically acceptable salts; in the structural formula, X is a hydrophilic head group, R1 is a carbonyl-containing saturated or unsaturated fatty chain, R2 is an iron-chelating group, and L is a bifunctional linker bond; Formula I.
[0019] In this invention, the hydrophilic head group X is one of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, or a derivative thereof; the structural formula is one of Formula II: Formula II; The carbon chain length of the carbonyl-containing saturated or unsaturated aliphatic chain R1 is 8~24; the structural formula is as shown in Formula III: Formula III; The iron chelating group R2 is one of derafloxacin, pyridones, catechols, pyrogallols, bispyridine methylamines, bispiperidine pyridines, amides, triazoles, deferoxones, deferoxamines, and their derivatives; or has a structural formula as shown in Formula IV. Formula IV; The bifunctional linker L is a saturated aliphatic chain with a carbon chain length of 0-10, with one end being an ester bond connected to the glycerol backbone and the other end being an amide bond connected to an iron chelating group; the structural formula is one of formula V: Formula V.
[0020] In this invention, the preferred structure of the iron-chelated phospholipid molecule includes: a hydrophilic head group X being phosphatidylcholine; a hydrophobic fatty chain R1 being a C18 fatty chain; an iron-chelating group R2 being deferasirox or a derivative thereof; and a bifunctional linker L being one of a saturated fatty chain with a carbon chain length of 2, 4, or 6. The iron-chelated phospholipid molecule is named Lyso-Cn-DFX (n=0, 2, 4, 6), and its structural formula is shown in Formula VI. Formula VI; More preferably, the structure of the iron-chelated phospholipid molecule preferably includes: the hydrophilic head group X is phosphatidylcholine; the hydrophobic fatty chain R1 is a C18 fatty chain; the iron chelating group R2 is derafloxacin or a derivative thereof; the iron-chelated phospholipid molecule is named Lyso-DFX, and its structural formula is as shown in Formula VII: Formula VII.
[0021] The iron-chelated phospholipid molecules of this invention can coordinate with iron ions and have good biocompatibility; the delivery carrier constructed from this compound can efficiently deliver bioactive molecules such as RNA drugs to the spleen.
[0022] This invention also provides the application of the iron-chelated phospholipid molecules described above in the preparation of lipid nanoparticles. The iron-chelated phospholipid molecules possess amphiphilic characteristics and can be used in the construction of lipid nanoparticles. The lipid nanoparticles prepared therefrom can serve as nucleic acid drug delivery carriers and form nucleic acid drug-lipid nanoparticle composite systems with nucleic acid drugs.
[0023] The present invention also provides a lipid nanoparticle comprising the following components: iron chelated phospholipid molecules as described in the above scheme, cationic lipids or ionizable lipids, neutral lipids, steroids and polyethylene glycol modified lipids; In this invention, the cationic lipid or ionizable lipid preferably includes at least one of 1,2-dilinoleoyloxy-3-dimethylaminopropane (DLinDMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), dilinoleoyl-3-dimethylaminopropanol (DLin-MC3-DMA), 1-octylnonyl8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]octanoate (SM-102), and ((4-hydroxybutyl)azadiyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), and the ionizable lipid is more preferably SM-102 or DLin-MC3-DMA; The neutral lipids preferably include 1,2-distearyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), and 1-palmitoyl-2 At least one of oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 2-dioleoyl-sn-glycero-3-phosphate-(1'-rac-glycerol) (DOPG), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and sphingomyelin (SM), more preferably 1,2-distearate-sn-glycero-3-phosphocholine (DSPC); The PEG-lipids preferably include 1,2-dimyristic-sn-glycerol-3-methoxy polyethylene glycol-2000 (DMG-PEG2000), 2-[(polyethylene glycol)-2000]-N,N-tetracosylacetamide (ALC-0159), 1,2-dimyristic-sn-glycerol methoxy polyethylene glycol (PEG-DMG), 1,2-distearate-sn-glycerol-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterol glycerol (PEG-DSG), PEG-dipalmitoyl, PEG-dioleyl, and PEG- -At least one of distearate, PEG-diacylglycerol amide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), PEG-phosphatidylethanolamine (PEG-PE), PEG-succinate diacylglycerol (PEG-S-DAG), PEG-ceramide (PEG-cer), PEG dialkoxypropyl carbamate and PEG-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA), more preferably 1,2-dimyristoyl-sn-glycerol-3-methoxy polyethylene glycol-2000 (DMG-PEG2000). Preferably, the steroid includes at least one of cholesterol, coprosterol, sitosterol, ergosterol, campesterol, stigmasterol, and rapeseed sterol, more preferably cholesterol.
[0024] In this invention, the preferred molar ratio of the iron-chelated phospholipid molecules, cationic lipids or ionizable lipids, neutral lipids, steroids and polyethylene glycol-modified lipids is (1~20):(20~60):(5~30):(20~50):(0.2~5); or (5~15):(40~60):(5~20):(20~40):(0.5~3); the preferred molar ratio of the iron-chelated phospholipid molecules, cationic lipids, neutral lipids, cholesterol and PEG-lipids is (5~15):(40~60):(5~20):(20~40):(0.5~3).
[0025] The present invention also provides a lipid nanoparticle delivery system, comprising the lipid nanoparticles described above and a bioactive component; the lipid nanoparticles contain iron-chelated phospholipid molecules as described above, and the bioactive component comprises one or more of DNA molecules, RNA molecules, proteins, peptides, and small molecule drugs.
[0026] In this invention, the bioactive component is negatively charged; the bioactive component is preferably nucleic acid, more preferably mRNA. In this invention, the iron-chelated phospholipid molecule, as one component of the lipid nanoparticles, enters the cell via endocytosis, fuses with the endosome / lysosomal membrane, and coordinates with divalent and trivalent iron ions therein to form phospholipid-iron complexes. This coordination can induce a transformation of the lipid structure of the endosome / lysosomal membrane from a stable lamellar phase to a non-lamellar phase, thereby significantly reducing the orderliness of the lipid bilayer, making the membrane structure looser and increasing its fluidity. Under the effect of the above structural transformation, the integrity of the endosome or lysosomal membrane is disrupted or its permeability is significantly increased, thereby promoting the efficient release of delivered nucleic acid molecules (such as mRNA) from the endosome into the cytoplasm, significantly improving the endosome escape efficiency. Furthermore, the efficient release of mRNA into the cytoplasm can significantly enhance its translational expression level and improve the expression efficiency of the target protein. The lipid nanoparticle delivery system described in this invention can achieve more efficient nucleic acid delivery and expression while ensuring low cytotoxicity, and can be used to improve the therapeutic effect in gene therapy, protein replacement therapy and tumor immunotherapy.
[0027] This invention also provides the application of the iron-chelated phospholipid molecules, nanoparticles, and lipid nanoparticle delivery systems described above in drug preparation. In this invention, the drug is used to target at least one of the heart, liver, spleen, lungs, and kidneys. The iron-chelated phospholipid molecules and lipid nanoparticles have advantages such as low cytotoxicity, good biocompatibility, and strong delivery capability. By loading bioactive components into the compounds or lipid nanoparticles, the bioactive components can be delivered to the heart, liver, spleen, lungs, and / or kidneys, which is beneficial for their efficacy.
[0028] The present invention also provides a pharmaceutical composition comprising the lipid nanoparticle delivery system described above and pharmaceutically acceptable excipients.
[0029] This invention also provides the application of iron-chelated phospholipid molecules, nanoparticles, lipid nanoparticle delivery systems, and pharmaceutical compositions as described above in improving drug delivery efficiency.
[0030] The present invention will be further described below with reference to specific embodiments. It should be understood that the embodiments are only used to illustrate the technical solutions of the present invention and do not constitute a limitation on the scope of protection of the present invention.
[0031] Example 1 Synthesis, purification and characterization of iron-chelated phospholipid Lyso-CO-DFX (Lyso-DFX).
[0032] 1. Synthesis and purification methods of Lyso-DFX.
[0033] Weigh 224 mg (0.6 mmol) of the deferasirox (DFX) analogue and add it to a 25 mL round-bottom flask. Add 2 mL of anhydrous chloroform to dissolve it. Separately weigh 145.94 mg (0.9 mmol) of N,N'-carbonyldiimidazole (CDI) and dissolve it in 1.5 mL of anhydrous chloroform. Slowly add the CDI dropwise to the above reaction system under stirring. React at 35 °C for 3 h under nitrogen protection to activate the carboxyl group in the DFX molecule.
[0034] Subsequently, 89.6 μL (0.6 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 157.20 mg (0.3 mmol) of 1-stearoyl-2-hydroxy-sn-glycerol-3-phosphatidylcholine (18:0 Lyso PC) were added sequentially to the reaction system. Lyso PC was pre-dispersed in 2 mL of anhydrous chloroform. The reaction system was stirred at 40 °C for 36 h under nitrogen protection.
[0035] After the reaction was completed, the reaction solution was purified by silica gel column chromatography. The elution system was a gradient elution of dichloromethane:methanol:water = 5:1:0 → 65:25:0 → 65:25:2 → 65:25:4.
[0036] After collecting the target product components, the organic solvent was removed by rotary evaporation, and the resulting product was further freeze-dried to finally obtain the target iron-chelated phospholipid Lyso-DFX; the synthetic route is as follows. Figure 1 As shown.
[0037] 2. The characterization method of Lyso-DFX.
[0038] (1) Nuclear magnetic resonance hydrogen spectrum ( 1 Characterization by H NMR: Weigh 5 mg of the Lyso-DFX freeze-dried sample and dissolve it in 0.55 mL of deuterated dimethyl sulfoxide (DMSO-d6). After the sample is completely dissolved, transfer the solution to a clean, dry NMR sample tube. Then, use an Ascend 400 / AVANCE III NMR spectrometer to analyze the sample. 1 1H NMR spectra were acquired and analyzed to confirm the chemical structure of the target compound Lyso-DFX.
[0039] Nuclear magnetic resonance test results (such as) Figure 2 As shown in the figure, the characteristic chemical shift signal of the obtained product is consistent with the structure of the target product Lyso-DFX, indicating that the product obtained in Example 1 is the target iron chelate phospholipid Lyso-DFX.
[0040] Example 2 Iron-chelated phospholipid Lyso-C n Synthesis, purification and characterization of -DFX (n=2, 4, 6).
[0041] 1. Lyso-C n - Methods for the synthesis and purification of DFX.
[0042] Weigh 200 mg (0.54 mmol) of Deferasirox (DFX) and add it to a 25 mL round-bottom flask, then disperse it in 2 mL of anhydrous chloroform. Separately weigh 130.4 mg (0.81 mmol) of N,N′-carbodiimidazole (CDI), dissolve it in 1 mL of anhydrous chloroform, and add it dropwise to the above DFX dispersion under stirring. Activate the solution at 35 °C for 3 h under nitrogen protection.
[0043] Subsequently, the amino acid linker molecule was dissolved in 1 mL of anhydrous chloroform, and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and the above reaction system were added sequentially. The reaction was carried out at 40 °C for 24 h under nitrogen protection.
[0044] The amino acid linking molecules are: β-alanine, used to prepare DFX-C2; 5-aminovaleric acid, used to prepare DFX-C4; and 7-aminoheptanoic acid, used to prepare DFX-C6.
[0045] After the reaction was completed, the product was purified by silica gel column chromatography (elution system was dichloromethane:methanol = 20:1 → 10:1), and the organic solvent was removed by rotary evaporation to obtain the intermediate DFX-Cn.
[0046] Weigh the above intermediate DFX-C n Approximately 0.45 mmol was added to a 25 mL round-bottom flask and dispersed in 2 mL of anhydrous chloroform. Separately, 0.68 mmol of CDI was weighed, dissolved in 1 mL of anhydrous chloroform, and added dropwise to DFX-C. n The dispersion was activated at 35°C for 4 hours under nitrogen protection.
[0047] Subsequently, 0.15 mmol of 1-stearoyl-2-hydroxy-sn-glycerol-3-phosphatidylcholine (18:0 Lyso PC) was dispersed in 1 mL of anhydrous chloroform and added sequentially with DBU (0.68 mmol) to the reaction system. The reaction was carried out at 40 °C for 24 h under nitrogen protection.
[0048] After the reaction was completed, the product was purified by silica gel column chromatography (elution system: dichloromethane:methanol:water = 65:25:0 → 65:25:2 → 65:25:4), the organic phase was removed by rotary evaporation, and finally the target product Lyso-C was obtained by freeze drying. n -DFX; A schematic diagram of the synthetic route for the iron-chelated phospholipid molecule Lyso-C2-DFX is shown below. Figure 3 As shown in the diagram, the synthetic route of the iron-chelated phospholipid molecule Lyso-C4-DFX is as follows. Figure 4 As shown in the diagram, the synthetic route of the iron-chelated phospholipid molecule Lyso-C6-DFX is as follows. Figure 5 As shown.
[0049] 2. Lyso-C n -DFX representation method.
[0050] (1) Nuclear magnetic resonance hydrogen spectrum ( 1 The detection methods for ¹H NMR and mass spectrometry are the same as in Example 1, except that the sample is Lyso-C. n Replace Lyso-DFX with -DFX, leave everything else unchanged.
[0051] Nuclear magnetic resonance test results (such as) Figures 6-8 As shown), the characteristic chemical shift signal of the obtained product is similar to that of the target product Lyso-C. n The structure of -DFX is consistent, indicating that the product obtained in Example 2 is the target iron-chelated phospholipid Lyso-C. n -DFX.
[0052] Example 3 This example illustrates the use of iron-chelated phospholipid Lyso-C. n The preparation methods, cytotoxicity, and physicochemical characterization of -DFX LNPs and reference formulation LNPs were described, including the determination of hydrodynamic particle size, aggregation-dispersion index (PDI), zeta potential, mRNA encapsulation efficiency (EE), and transfection efficiency.
[0053] The specific formulations of each LNP group are as follows: Group F0 is a four-component LNP containing Dlin-MC3-DMA, with the molar ratio of Dlin-MC3-DMA:DSPC:Cholesterol:DMG-PEG. 2k =50:10:38.5:1.5; A1~A9 and B1~B7 are five-component LNPs constructed by introducing Lyso-DFX on the basis of the above Dlin-MC3-DMA system. Different formulations are formed by adjusting the proportion of each component in each group. The molar ratios of each component are shown in Table 1 and Table 2. Table 1. Molar ratios of each component in groups F0 and A1~A9
[0054] Table 2. Molar ratios of each component in groups F0 and B1~B7
[0055] Group S0 is a four-component LNP based on ionizable lipid SM-102, with the corresponding molar ratio of SM-102:DSPC:Cholesterol:DMG-PEG. 2k =50:10:38.5:1.5; C1 to C6 are five-component LNPs constructed by introducing Lyso-DFX on the basis of the SM-102 system. Different formulations are formed by adjusting the proportion of each component in each group. The molar ratio of each component is shown in Table 3.
[0056] Table 3. Molar ratios of each component in groups S0 and C1~C6
[0057] (1) LNP preparation method.
[0058] 1. Preparation of LNP by ethanol dilution method.
[0059] LNPs were prepared using the ethanol dilution method. First, fireflyluciferase mRNA was dissolved in 25 mM sodium citrate buffer (pH 4.0) as the aqueous phase.
[0060] The lipid component was then dissolved in anhydrous ethanol to form an organic phase. The lipid component included iron-chelated phospholipid Lyso-C. n -DFX, ionized lipids Dlin-MC3-DMA or SM-102, DSPC, cholesterol, and DMG-PEG2000.
[0061] Under vigorous mixing conditions, the aqueous phase and organic phase were rapidly mixed at a volume ratio of 3:1 (H2O:EtOH), and then rapidly mixed by pipetting, followed by vortexing for 20 s. The mixed system was then incubated at room temperature for 20 min to allow the lipid components to self-assemble into LNPs.
[0062] The resulting suspension was purified and concentrated using Amicon ultrafiltration centrifuge tubes (MWCO: 100 kDa) to remove unencapsulated mRNA and organic solvents. The final product was the iron-chelated phospholipid Lyso-C. n -DFX LNPs, and store at 4°C for later use.
[0063] 2. Preparation of LNPs using microfluidic methods.
[0064] First, firefly luciferase mRNA was dissolved in 25 mM sodium citrate buffer (pH 4.0) as the aqueous phase. The lipid fraction was then dissolved in anhydrous ethanol to form the organic phase. The lipid fraction included iron-chelated phospholipid Lyso-C. n -DFX, ionized lipids Dlin-MC3-DMA or SM-102, DSPC, cholesterol, and DMG-PEG2000.
[0065] Nanoparticles were then prepared using Cytiva's NanoAssemblr™ Ignite™ nanoparticle preparation system. The aqueous and organic phases were injected into the two inlet channels of the microfluidic chip, respectively, and rapidly mixed at a total flow rate (TFR) of 6–20 mL / min and a flow rate ratio (FRR) of 3:1 (aqueous phase:organic phase). This allowed the lipid components and mRNA to spontaneously self-assemble at the microscale to form LNPs.
[0066] The resulting nanoparticle solution was purified and concentrated using Amicon ultrafiltration centrifuge tubes (MWCO: 100kDa) to remove ethanol and free mRNA. Finally, iron-chelated phospholipid Lyso-DFX LNPs were obtained and stored at 4°C for later use.
[0067] Lyso-C, an iron-containing chelated phospholipid prepared by the above method n -DFX's LNPs have uniform particle size and good stability, and can effectively encapsulate mRNA for subsequent in vitro and in vivo experiments.
[0068] (2) Particle size, PDI and Zeta potential were measured.
[0069] The prepared LNPs were diluted to 10 μg / mL with PBS buffer (10 mM, pH 7.4). One mL of the diluted nanoparticle suspension was transferred to a particle size distribution cuvette, and its hydrodynamic particle size and PDI were determined using dynamic light scattering (DLS).
[0070] The sample was then transferred to a Malvern potential detection cell to measure the Zeta potential in order to evaluate the surface charge characteristics and colloidal stability of the nanoparticle system.
[0071] (3) mRNA encapsulation rate determination.
[0072] The encapsulation efficiency of mRNA in LNPs was determined using the Quant-iT™ RiboGreen™ RNA kit, purchased from Thermo Fisher Scientific, Co., Ltd. The assay was performed according to the kit instructions. The mRNA encapsulation efficiency (EE) was calculated using the following formula: EE(%)=Encapsulated RNA concentration / Total RNA concentration×100%.
[0073] (4) Cytotoxicity assay.
[0074] The cytotoxicity of different formulations of LNPs at different concentrations and treatment times was determined using the MTT assay.
[0075] When the cell confluence in a 100mm cell culture dish reached 80%–90%, HEK-293T cells (human embryonic kidney cell line, purchased from Wuhan Pronosai Life Science Technology Co., Ltd.) were seeded into 96-well cell culture plates, with 1 × 10⁶ cells per well. 4 Each cell.
[0076] After culturing the cells at 37°C and 5% CO2 for 24 hours, the cell confluence was approximately 70%. Subsequently, different formulations of LNPs were added for treatment, and the final mRNA concentration per well was 0.4 μg / mL.
[0077] After culturing the cells for another 24 hours, the original culture medium was discarded, and 100 μL of culture medium containing 0.5 mg / mL MTT was added to each well. The cells were then incubated at 37°C for 4 hours.
[0078] After incubation, discard the culture medium containing MTT and add 100 μL of dimethyl sulfoxide (DMSO) to each well to dissolve the generated purple formazan crystals. Then place the culture plate on a shaker and shake for 20 min to fully dissolve the crystals.
[0079] The absorbance of each well was measured at 490 nm using a SpectraMax M2 multi-functional microplate reader. Data from each experimental group were normalized with the untreated cell group as a control to evaluate the cytotoxicity of different LNP formulations.
[0080] (5) Determination of mRNA transfection efficiency.
[0081] When the cell confluence in a 100mm cell culture dish reaches 80%–90%, HEK-293T cells are seeded into 96-well white transparent cell culture plates, with 1 × 10⁶ cells seeded per well. 4 Each cell.
[0082] After culturing the cells at 37°C and 5% CO2 for 24 hours, the cell confluence was approximately 70%, and then transfection experiments were performed.
[0083] Different formulations of LNPs containing 0.1 μg / mL firefly luciferase mRNA were added to each well for treatment, and the mixture was incubated at 37°C and 5% CO2 for 24 h.
[0084] After the culture was completed, the original culture medium was discarded, and 40 μL of lysis buffer (provided by the luciferase assay kit) was added to each well. The 96-well plate was then placed on ice for lysis for 30 min. Subsequently, 100 μL of firefly luciferase assay reagent (provided by the luciferase assay kit) was added to each well and incubated at room temperature for 5 min.
[0085] Finally, the luminescence intensity of each well was measured using a fully automated multifunctional enzyme-linked immunosorbent assay (ELISA) platform (FlexStation3). The experimental results were normalized using the F0 treatment group as a control to evaluate the effects of adding iron-chelated phospholipids Lyso-C with different carbon chain lengths. n -DFX-enhanced LNPs mRNA delivery efficiency and expression levels in cells.
[0086] The data in the table are the average values of multiple repeated experiments, and the cell experiment results are represented by standardized expression signals.
[0087] The results (as shown in Table 4) indicate that in the Dlin-MC3-DMA system, formulation B5 exhibited superior mRNA expression efficiency, good physicochemical properties, and low cytotoxicity; while in the SM-102 system, formulation C4 exhibited superior mRNA expression efficiency, good physicochemical properties, and low cytotoxicity.
[0088] Further comparison revealed that the C4 formulation exhibited higher expression efficiency than the B5 formulation, while also possessing acceptable particle size distribution, encapsulation efficiency, and cytotoxicity. Therefore, the C4 formulation was selected as the optimized formulation for subsequent studies and is defined as follows: L1: Optimized five-component formulation LNP containing Lyso-DFX (C4 in Table 4); Accordingly, the control group S0 prescription was defined as: L0: A four-component commercial formulation LNP (S0 in Table 4) without Lyso-DFX.
[0089] The above results indicate that the introduction of Lyso-DFX can improve the mRNA delivery and expression efficiency without significantly affecting the physicochemical properties and biocompatibility of LNPs. Furthermore, the iron-chelated phospholipid Lyso-DFX LNPs prepared above have high mRNA encapsulation efficiency and good particle size distribution characteristics, making them suitable for subsequent in vitro and in vivo delivery studies.
[0090] Table 4 Physicochemical properties of iron-chelated phospholipids (LNPs)
[0091] Example 4 This embodiment is used to evaluate Lyso-C, an iron-chelated phospholipid containing different carbon chain lengths. n -DFX's five-component LNPs mRNA delivery capability, screening for optimal structure.
[0092] (1) Preparation of LNP.
[0093] Lipid nanoparticles were prepared using the same method as described in Example 3 above, based on Dlin-MC3-DMA (MC3). Based on the four-component LNP formulation F0, iron-chelated phospholipids Lyso-C with different carbon chain lengths were introduced into the system. n -DFX, with the specific ratio of A7 and B5 in Table 1, were used to obtain different experimental groups.
[0094] In the Lyso-Cn-DFX, n represents the number of carbon atoms in the connecting chain, including: A7-0C, B5-0C: Lyso-DFX (n=0); A7-2C, B5-2C: Lyso-C2-DFX (n=2); A7-4C, B5-4C: Lyso-C4-DFX (n=4); A7-6C, B5-6C: Lyso-C6-DFX (n=6); A total of 9 experimental groups were set up (including the unmodified control group F0 in Table 1).
[0095] Each LNP group contained Luciferase mRNA, and its preparation method was the same as that in Example 4 above.
[0096] (2) Determination of mRNA transfection efficiency.
[0097] HEK-293T (human embryonic kidney cell line) cells were used for in vitro transfection experiments. The operation and detection methods of the transfection experiments were the same as those for the determination of mRNA transfection efficiency in Example 3. Lyso-DFX was replaced with LNPs after iron chelate phospholipids Lyso-Cn-DFX with different carbon chain lengths.
[0098] (3) Results and analysis.
[0099] Experimental results show (e.g.) Figure 9 As shown in the figure, Lyso-DFX (n=0) without additional carbon chain modifications exhibited the best mRNA delivery efficiency, with its expression level significantly higher than other chain length structures. As the linker chain length increased (n=2, 4, 6), the transfection efficiency decreased. Therefore, the optimal formulation remained L1 in subsequent formulations, and Lyso-DFX was not replaced.
[0100] Example 5 This embodiment is used to evaluate the delivery efficiency and cytotoxicity of iron-chelated lipid nanoparticles in different cells, at different times and with different mRNA doses.
[0101] (1) mRNA delivery efficiency and expression level of lipid nanoparticles in different cells.
[0102] When the cell confluence in the 100mm cell culture dish reached 80%–90%, HEK-293T cells (human embryonic kidney cell line), HepG2 cells (human liver cancer cell line, purchased from Wuhan Pronosei Biotechnology Co., Ltd.), RAW264.7 cells (mouse macrophage cell line, from the National Key Laboratory of Medicinal Chemistry and Biology, Nankai University), and chondrocytes (primary cells derived from mouse cartilage, primary cells extracted from C57BL / 6 mouse cartilage) were seeded into white enzyme-free 96-well plates, with 1 × 10⁶ cells per well. 4 Each cell.
[0103] After culturing the cells at 37°C and 5% CO2 for 24 hours, the cell confluence was approximately 70%, and then transfection experiments were performed.
[0104] Iron-chelated LNPs (B5, C4) containing 0.1–1 μg / mL firefly luciferase mRNA and a reference formulation (F0, S0) with the same mRNA concentration were added to each well for treatment, and the mixture was cultured at 37°C and 5% CO2 for 24 h. The luciferase expression intensity was determined as described in Example 3 (5).
[0105] (2) Cytotoxicity of lipid nanoparticles in different cells.
[0106] The cytotoxicity of different formulations of LNPs at different concentrations and treatment times was determined using the MTT assay.
[0107] When the cell confluence in a 100mm cell culture dish reaches 80%–90%, HEK-293T cells (human embryonic kidney cell line) are seeded into 96-well cell culture plates, with 1 × 10⁶ cells per well. 4 Each cell.
[0108] After culturing the cells at 37°C in a 5% CO2 incubator for 24 hours, the cell confluence was approximately 70%. Subsequently, different formulations of LNPs were added for treatment, resulting in a final mRNA concentration of 0.4–1 μg / mL per well. Cell viability was measured as described in Example 3.
[0109] Experimental results show (e.g.) Figure 10 As shown in the figure, the five-component LNPs with added iron chelated phospholipids were able to achieve efficient mRNA delivery in HEK-293T cells, human hepatocellular carcinoma cells HepG2, mouse macrophages RAW264.7, and chondrocytes. Compared with the reference formulation, it produced a significant enhancement of luciferase expression signal without increasing cytotoxicity, indicating that the delivery system has stronger in vitro transfection capability and broad bioapplicability.
[0110] Example 6 This embodiment is used to study the uptake behavior of B5 in cells and its co-localization with lysosomes compared to F0.
[0111] First, LNPs with different formulations loaded with Cy5-labeled luciferase mRNA were prepared according to the method in Example 3, specifically by using Cy5-labeled luciferase mRNA instead of ordinary luciferase mRNA.
[0112] Cell culture: The culture method for HepG2 cells is the same as that in Example 5.
[0113] HepG2 cells were planted at a density of 1 × 10⁶ cells per well. 4 Cells were seeded at a density of 1000 mcg / well in black 96-well plates and cultured at 37°C for 24 hours. Cells were then pretreated for 0.5 hours with different inhibitors: methyl-β-cyclodextrin (MβCD) 2mM, chlorpromazine (CPZ) 10μg / mL, and EIPA 20μM. Lipid nanoparticles (B5 or L1) were added and co-incubated with the inhibitors for 1 hour, maintaining an mRNA concentration of 0.4μg / mL. The original culture medium was discarded, and 40μL of lysis buffer (from the luciferase assay kit) was added to each well. The culture plates were then placed on ice for lysis for 30 minutes. Cy5 fluorescence signal was detected (excitation wavelength 645nm, emission wavelength 670nm).
[0114] HepG2 cells were planted at a density of 1 × 10⁶ cells per well. 5The prepared lipid nanoparticles were seeded at a density of 10 μm in 20 mm confocal culture dishes and incubated for 24 h. The prepared lipid nanoparticles were then diluted with serum-free medium and added to the confocal culture dishes, with a mRNA concentration of 0.7 μg / mL. After further incubation for 1 h and 2 h, the original medium was discarded, and 200 μL of medium containing 75 nM Lyso-Tracker Green lysosomal probe was added to each dish. After incubation for 30 min, unbound dye was removed, and the samples were washed three times with PBS. Imaging was then performed using a Leica TCSSP8 laser confocal microscope (Lyso-Tracker Green: excitation wavelength 488 nm / emission wavelength 503–550 nm; Cy5: excitation wavelength 638 nm / emission wavelength 650–700 nm). Image processing and colocalization analysis were performed using ImageJ software, and the degree of colocalization was evaluated using the Pearson correlation coefficient. All experiments were performed in triplicate.
[0115] Experimental results show (results as follows) Figure 11 As shown in the figure, compared with the original prescription F0 group, the B5 group showed higher intracellular signal intensity and lower lysosomal colocalization in the cells, indicating that the system can promote mRNA uptake and escape from endosomes / lysosomes, thereby improving nucleic acid delivery efficiency.
[0116] Example 7 This embodiment uses absorption spectroscopy in the 400-800 nm range to monitor the interaction between Lyso-DFX and Fe under different pH conditions. 2+ The chelation situation.
[0117] Fe 2+ Solution preparation: Weigh 5.73 mg of triazine (NTA) (30 μmol) and dissolve it in 8 mL of PBS buffer (pH 7.4, 6.3, 5.5, 10 mM) using sonication. Add 0.1 mL of 0.1 M ferrous ammonium sulfate standard solution to the system, and then adjust the pH of the solution to 7.4, 6.3, and 5.5 by adding 1 mM sodium hydroxide solution. Finally, bring the volume to 10 mL with PBS buffer (pH 7.4, 6.3, 5.5, 10 mM).
[0118] Preparation of lipid suspension: Accurately weigh 1.76 mg of Lyso-DFX and dissolve it in 1 mL of chloroform. Place the solution in a 10 mL flask and rotary evaporate at 40 °C for 30 minutes. Then, place the flask in an oven to dry for 12 hours to form a thin lipid film. Add 1 mL of PBS solution (pH 7.4, 6.3, 5.5, 10 mM) to the flask and sonicate for 20 minutes to obtain the Lyso-DFX lipid suspension.
[0119] To obtain the UV-Vis absorption spectra of the samples in the wavelength range of 400–800 nm under different pH conditions, a 2 mM Lyso-DFX lipid suspension was mixed with a 1 mM Fe... 2+ The solutions are mixed in a 1:1 volume ratio to initiate the chelation reaction. During mixing, it is essential to ensure that the pH levels are appropriately matched.
[0120] The results show (e.g.) Figure 12 As shown in the figure, a new absorption peak appears at 500 nm, and the intensity of this absorption peak changes with pH conditions, indicating that Lyso-DFX has a positive effect on Fe at pH 7.4. 2+ It exhibits the strongest affinity, with the weakest affinity at pH 5.5. The chelate is red, and the more chelates present, the deeper the red color.
[0121] Example 8 This embodiment primarily uses differential scanning calorimetry (DSC) to analyze phase transitions, melting points, glass transition temperatures, crystallinity, and thermal stability by measuring the thermal changes of substances during heating or cooling. When Lyso-DFX reacts with Fe... 2+ When chelates form, their structure changes, leading to alterations in thermal properties: the melting peak of the chelate shifts to the left, indicating a looser molecular arrangement and reduced order. Differential scanning calorimetry (DSC) was used to study the properties of Lyso-DFX in combination with Fe. 2+ Changes in properties before and after chelation. Fe 2+ The preparation of the solution and the lipid suspension are the same as in Example 7.
[0122] Unchelated Fe 2+ Lyso-DFX was removed by dialysis with water using a dialysis bag (MWCO: 1000 Da) for 18 hours. After dialysis, the solution was freeze-dried to obtain a reddish-brown powder. 5 mg of Lyso-DFX and its reaction with Fe... 2+ The resulting chelates were weighed into graduated cylinders for DSC temperature scanning, and all DSC measurements were performed at a scan rate of 20°C / min.
[0123] The results show (e.g.) Figure 13 As shown in the figure, Lyso-DFX can form a complex with iron ions and cause its phase transition temperature to change.
[0124] Example 9 This embodiment evaluates the membrane-disrupting activity of Lyso-DFX through a hemolysis test.
[0125] Red blood cells (RBCs) were separated from freshly collected mouse whole blood by centrifugation at 3500g for 15 minutes. The RBCs were then washed five times with PBS (pH 7.4, 10mM) until the supernatant became colorless. Lyso-DFX lipid suspensions at pH 7.4 and 5.5 were prepared according to the method described in Example 7 and mixed with an equal volume of RBC suspension to achieve final Lyso-DFX concentrations of 0.125, 0.25, and 0.5mM, respectively. After incubation at 37°C for 1 hour, the RBC suspensions were centrifuged at 3500g for 10 minutes, and the supernatant containing hemoglobin was collected. Hemoglobin levels were measured at 540 nm using a multi-mode microplate reader (SpectraMax M2). Red blood cell suspensions incubated with Lyso-DFX-free PBS solution (pH 7.4, 5.5, 10 mM) were used as negative controls, and red blood cell suspensions incubated with Triton X-100 solution (1% (v / v)) were used as positive controls. The percentage of hemolysis was calculated.
[0126] The results show (e.g.) Figure 14 As shown in the figure, under neutral pH conditions, Lyso-DFX exhibited a low hemolysis rate, indicating its good biocompatibility. Notably, under acidic pH conditions, the hemolysis rate of Lyso-DFX increased significantly, exhibiting a concentration-dependent hemolytic activity. This phenomenon can be attributed to the iron-chelating ability of Lyso-DFX and the presence of Fe in the microenvironment. 2+ Availability. Compared to the exogenously added Fe in Example 7. 2+ Unlike the Fe in this embodiment, 2+ Iron ions originate from hemoglobin released within red blood cells. Although the chelation efficiency of each Lyso-DFX molecule is low under acidic conditions (pH 5.5), the chelation efficiency of Fe from hemoglobin increases under low pH conditions. 2+ Easier to release. This leads to free Fe in the system 2+ Increased concentration promotes the formation of the Lyso-DFX-Fe chelate complex, thereby enhancing its membrane-disrupting activity and manifesting as an increased hemolysis rate.
[0127] Example 10 6-Dodecanoyl-2-dimethylaminonaphthalene (Laurdan) is a polarity-sensitive fluorescent probe used to analyze membrane lipid raft structures. The generalized polarization (GP) value is a parameter calculated by measuring the change in fluorescence emission intensity of Laurdan at different excitation wavelengths, reflecting the degree of order in the membrane. A high GP value generally indicates a more ordered gel phase, characterized by a tightly packed membrane structure, lower polarity, and a shift of the Laurdan emission peak towards the blue region (440 nm). Conversely, a low GP value indicates a more disordered liquid crystal phase, characterized by high fluidity, high polarity, and a shift of the emission peak towards the green region (490 nm). In practical biological membranes, this value typically ranges from -0.5 (liquid disorder) to +0.5 (solid order). GP changes only with phase and is unaffected by changes in polar head groups or pH within the range of 4 to 10.
[0128] Ctl group model endosome vesicles (with or without encapsulated Fe) 2+ Preparation: The control group (Ctl) contained 50 mol% POPC, 25 mol% DOPE, and 25 mol% cholesterol. Phospholipid solutions of the corresponding mass were weighed according to the molar ratio of each component, dissolved in chloroform, and placed in a 25 mL flask. The solution was then rotary evaporated at 40 °C for 30 minutes, followed by drying in an oven for 12 hours to form a thin lipid membrane.
[0129] Add Fe-containing or Fe-free to the flask 2+ PBS solutions (pH 7.4, 6.3, 5.5, 10 mM) prepared according to the method in Example 7 were then vortexed to obtain vesicle suspensions. Further hydration was achieved by incubating the suspensions at 60°C for 20 minutes.
[0130] To obtain two different vesicle structures, the vesicles were extruded using an Avanti extruder heated to 55°C (phospholipid phase transition temperature): the larger vesicles were extruded through an 800 nm polycarbonate membrane, while the smaller vesicles were extruded through a 200 nm polycarbonate membrane.
[0131] Subsequently, a desalting column was used to remove free Fe from the sample. 2+ And other ions, thereby avoiding interference caused by excessive ions during the detection process.
[0132] Laurdan stock solution dissolved in DMSO was added to each group of samples to achieve a final concentration of 10 μM. After incubation at 37°C for 2 hours to allow the Laurdan probe to be fully embedded in the vesicles, Lyso-DFX was added to final concentrations of 0, 50, 100, and 200 μM, respectively. The samples were then incubated at 37°C for another 24 hours, and fluorescence intensity (excitation wavelength 350 nm, emission wavelengths 440 / 490 nm) was measured using a multi-functional microplate reader (SpectraMax M2). The generalized polarization value (GP) was calculated using the following formula: GP = (I440 - I490) / (I440 + I490), where I440 or I490 represents the fluorescence intensity of Laurdan at 440 nm or 490 nm under 340 nm excitation light, respectively.
[0133] The results show (e.g.) Figure 15 As shown in the figure, after the addition of Lyso-DFX, the GP value decreased from approximately 0.11 to approximately -0.35, indicating that the insertion of Lyso-DFX into the vesicles enhanced membrane fluidity. In Fe... 2+ In its presence, adding Lyso-DFX reduced the GP value from approximately 0.12 to approximately -0.45, indicating that Lyso-DFX is related to Fe 2+ The chelation effect further enhances the membrane fluidity of lipids.
[0134] Example 11 Endosomes are vesicle structures formed by invagination of the cell membrane, with subtle differences in lipid composition and ratio between their outer membrane and the cell membrane. This embodiment simulates a phospholipid bilayer vesicle system composed of endosomes to investigate the role of Lyso-DFX and iron ion chelation in the endosome escape process.
[0135] The control group (Ctl) contained 50 mol% POPC, 25 mol% DOPE, and 25 mol% cholesterol; The 10 mol% Lyso-DFX group contained 45 mol% POPC, 22.5 mol% DOPE, 22.5 mol% cholesterol, and 10 mol% Lyso-DFX. The 25mol% Lyso-DFX group contains 37.5mol% POPC, 18.75mol% DOPE, 18.75mol% cholesterol, and 25mol% Lyso-DFX.
[0136] Weigh out the appropriate amount of phospholipids according to the molar ratio of each component, dissolve them in chloroform, place them in a 25 mL flask, and rotary evaporate at 40 °C for 30 minutes. Then place them in an oven to dry for 12 hours to finally form a thin lipid film.
[0137] D2O was used instead of PBS buffer during hydration; to control hydrodynamic dimensions, sonication was used instead of extrusion, specifically a 100W sonic cell disruptor was used to sonicate the vesicles for 5 minutes.
[0138] Weigh 5.73 mg of triazine (NTA) (30 μmol) and dissolve it in 8 mL of D₂O (pH 7.4, 6.3, 5.5, 10 mM) using sonication. Add 0.1 mL of 0.1 M ferrous ammonium sulfate standard solution to the system, then adjust the pH of the solution to 7.4, 6.3, and 5.5 by adding 1 mM sodium hydroxide solution. Finally, bring the volume to 10 mL with D₂O (pH 7.4, 6.3, 5.5, 10 mM).
[0139] Fe 2+ The solution was mixed with Lyso-DFX solution to obtain Lyso-DFX and Fe, respectively. 2+ Mixtures with molar ratios of 2:1, 1:1, and 1:2 were prepared. Samples were transferred to clean, dry NMR tubes and then analyzed using a Bruker 600MHz NMR spectrometer with or without Fe. 2+ The 31P NMR signal of the samples was detected under the following conditions. The total lipid concentration was set to 20 mM, and the acquisition parameters required 7500 scans per sample to ensure sufficient signal-to-noise ratio and spectral quality.
[0140] The results show (e.g.) Figure 16 (As shown) In the absence of iron ions, all groups exhibited characteristic peaks of the lipid laminar phase; after the addition of iron ions, the control group showed no significant changes, and the characteristic laminar phase of vesicles containing Lyso-DFX disappeared, showing characteristic peaks of the hexagonal phase or free phospholipids, indicating that the interaction between Lyso-DFX and iron ions can cause changes in the conformation of the contents, destroy its integrity, and promote the release of contents.
[0141] Example 12 This embodiment is used to evaluate the effects of L1 and L0 on the organ distribution of mRNA in mice.
[0142] The experimental subjects were 4-8 week old female BALB / c mice. Mice were randomly divided into two groups of four mice each, and each group was given different formulations of LNPs with the same mRNA concentration. Each mouse was administered 0.25 mg / kg Luciferase mRNA via intravenous (IV) injection. Six hours after administration, the mice were injected intraperitoneally with D-Luciferase substrate at a dose of 150 mg / kg for in vivo fluorescence detection.
[0143] Six hours after drug administration, bioluminescence imaging was performed using the In Vitro Animal Imaging System (IVIS Spectrum). Whole-body imaging was first performed on anesthetized mice, followed by organ imaging after dissection. Based on the imaging results, the distribution of LNPs in major organs and tissues was analyzed, including the heart, liver, spleen, lungs, and kidneys.
[0144] The results show (e.g.) Figure 17 As shown in the figure, the L1 group containing Lyso-DFX can achieve extrahepatic targeting in mice, mainly expressed in the spleen.
[0145] Example 13 This embodiment was used to evaluate the anti-tumor therapeutic effect of L1 and L0 delivery of tumor antigen mRNA as a therapeutic tumor vaccine in a melanoma model. The selected tumor model was mouse melanoma cells B16-F10 / OVA (from the State Key Laboratory of Medicinal Chemistry and Biology, Nankai University) that stably express ovabumin (OVA).
[0146] (1) Tumor cell culture.
[0147] B16-F10 / OVA cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (10,000 U / mL) and maintained at 37°C in a 5% CO2 incubator. When cell confluence reached approximately 80%, the cells were digested with trypsin and resuspended in PBS for use in animal experiments.
[0148] (2) Establishment of a mouse model of melanoma.
[0149] Female C57BL / 6 mice aged 6-8 weeks were selected. B16-F10 / OVA cells in the logarithmic growth phase were collected by centrifugation, resuspended in PBS, and the cell concentration was adjusted to 5 × 10⁻⁶. 6 cells / mL. 5 × 10⁵ cells / mL were injected subcutaneously into each mouse. 5 A subcutaneous melanoma xenograft model was established using 100 μL of cells. Animal ethics were strictly followed during the experiment, and the tumor dimensions were kept to a minimum of 20 mm.
[0150] (3) LNP formulations and dosing regimens.
[0151] The experiment was set up with three groups: PBS group, L0-LNP-OVA group, and L1-LNP-OVA group.
[0152] Both LNPs contain OVA-mRNA.
[0153] The drug was administered to mice starting on day 3 after tumor inoculation, via tail vein injection, once every 3 days.
[0154] The mRNA dosage is 0.5 mg / kg, approximately 10 μg per mouse, with an injection volume of approximately 100 μl.
[0155] (4) Tumor growth monitoring.
[0156] Throughout the experiment, changes in tumor volume and body weight in the mice were recorded daily. Tumor volume was calculated using the following formula: V = (L × W) 2 ) / 2; Where L is the long diameter of the tumor and W is the short diameter of the tumor.
[0157] The experiment continued until day 16, when all mice were euthanized. Blood samples were collected by taking blood from the eyeballs, and the plasma was separated by centrifugation for the detection of blood biochemical indicators ALT, AST, BUN, and CRE.
[0158] The following tissues were collected simultaneously: heart, liver, spleen, lungs, kidneys, and tumor tissue.
[0159] All tissue samples were divided in half. One half was used for paraffin embedding and tissue sectioning, while the other half was flash-frozen and stored at -80°C.
[0160] Tumor and spleen tissues were embedded in paraffin and sectioned for CD8a immunofluorescence staining to assess CD8 levels. + T cell infiltration in tumor tissue. Tumor tissue frozen at -80°C was used to prepare tissue homogenates, and the levels of TNF-α and IFN-γ cytokines were detected by ELISA.
[0161] The results show (e.g.) Figure 18 As shown in the figure, compared with the L0 group, the L1 group showed a more significant tumor growth inhibitory effect in the melanoma model, and the L1 group also showed higher levels of CD8 in tumor tissue and spleen. + The increased T cell infiltration level, along with significantly elevated expression of TNF-α and IFN-γ, suggests that this system can enhance the anti-tumor immune response. Meanwhile, serum indicators showed that it did not cause significant adverse reactions.
[0162] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.
Claims
1. An iron-chelated phospholipid molecule, characterized in that, The iron-chelated phospholipid molecule is a phospholipid derivative with an amphiphilic structure, comprising a hydrophilic head group and a hydrophobic fatty chain, wherein the hydrophobic fatty chain has an iron chelating group; the iron-chelated phospholipid molecule comprises one of the structural formulas of Formula I, or its tautomers, stereoisomers, solvates or pharmaceutically acceptable salts; in the structural formula, X is a hydrophilic head group, R1 is a carbonyl-containing saturated or unsaturated fatty chain, R2 is an iron chelating group, and L is a bifunctional linker bond; Formula I.
2. The iron-chelated phospholipid molecule according to claim 1, characterized in that, The hydrophilic head group X is one of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, or a derivative thereof; the carbon chain length of the carbonyl-containing saturated or unsaturated aliphatic chain R1 is 8-24; the iron chelating group R2 is one of derafloxacin, pyridones, catechols, pyrogallols, bispyridinemethylamines, bispiperidinepyridines, amides, triazoles, deferoxones, deferoxamines, or their derivatives; the bifunctional linker L is a saturated aliphatic chain with a carbon chain length of 0-10, with one end being an ester bond connected to the glycerol backbone and the other end being an amide bond connected to the iron chelating group.
3. The iron-chelated phospholipid molecule according to claim 1, characterized in that, The hydrophilic head group X is phosphatidylcholine, the hydrophobic fatty chain R1 is a C18 fatty chain, the iron chelating group R2 is derafloxacin or a derivative thereof, and the bifunctional linker L is one of the saturated fatty chains with carbon chain lengths of 2, 4, or 6.
4. The iron-chelated phospholipid molecule according to claim 3, characterized in that, The hydrophilic head group X is phosphatidylcholine; the hydrophobic fatty chain R1 is a C18 fatty chain; and the iron chelating group R2 is derafloxacin or a derivative thereof.
5. The use of the iron-chelated phospholipid molecules as described in any one of claims 1 to 4 in the preparation of lipid nanoparticles.
6. A lipid nanoparticle, characterized in that, It includes the following components: the iron chelated phospholipid molecule of claim 1, cationic lipids or ionizable lipids, neutral lipids, steroids and polyethylene glycol modified lipids; The molar ratio of the iron-chelated phospholipid molecules, cationic lipids or ionizable lipids, neutral lipids, steroids and polyethylene glycol-modified lipids is (1~20):(20~60):(5~30):(20~50):(0.2~5); or (5~15):(40~60):(5~20):(20~40):(0.5~3).
7. A lipid nanoparticle delivery system, characterized in that, It includes the lipid nanoparticles as described in claim 6 and the bioactive components; the lipid nanoparticles contain the iron chelated phospholipid molecules as described in claim 1, and the bioactive components include one or more of DNA molecules, RNA molecules, proteins, peptides, and small molecule drugs.
8. The application of the iron-chelated phospholipid molecules as described in claims 1 to 4, the nanoparticles as described in claim 6, and the lipid nanoparticle delivery system as described in claim 7 in drug preparation.
9. A pharmaceutical composition, characterized in that, Includes the lipid nanoparticle delivery system of claim 7 and pharmaceutically acceptable excipients.
10. The use of the iron-chelated phospholipid molecules of claims 1-4, the nanoparticles of claim 6, the lipid nanoparticle delivery system of claim 7, and the pharmaceutical composition of claim 9 in improving drug delivery efficiency.
